829702804	829702804	CD	B-NP	O
|	|	NN	I-NP	O
ODP	ODP	NN	I-NP	O
|	|	NN	I-NP	O
48073380	48073380	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
7897353	7897353	CD	B-NP	O
|	|	CC	I-NP	O
2/6/2006	2/6/2006	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	B-protein
CHF	CHF	NNP	I-NP	I-protein
|	|	NNP	I-NP	O
|	|	NNP	I-NP	O
DIS	DIS	NNP	I-NP	O
|	|	NNP	I-NP	O
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
2/20/2006	2/20/2006	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Discharge	Discharge	NNP	B-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
10/7/2006	10/7/2006	CD	B-NP	O
******	******	SYM	I-NP	O
FINAL	FINAL	NN	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
ORDERS	ORDERS	NN	I-NP	O
******	******	SYM	B-NP	O
FINWALL	FINWALL	NN	I-NP	O
,	,	,	O	O
ROGER	ROGER	NNP	B-NP	O
A	A	NNP	I-NP	O
457-70-33-6	457-70-33-6	POS	B-NP	O
Co	Co	NNP	I-NP	O
Service	Service	NNP	I-NP	O
:	:	:	O	O
MED	MED	NNP	B-NP	O
DISCHARGE	DISCHARGE	NNP	I-NP	O
PATIENT	PATIENT	NNP	I-NP	O
ON	ON	NNP	I-NP	O
:	:	:	O	O
10/24/06	10/24/06	CD	B-NP	O
AT	AT	NN	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
PM	PM	NNP	I-NP	O
CONTINGENT	CONTINGENT	NNP	I-NP	O
UPON	UPON	NNP	I-NP	O
Not	Not	NNP	I-NP	O
Applicable	Applicable	NNP	I-NP	O
WILL	WILL	NNP	I-NP	O
D/C	D/C	NNP	I-NP	O
ORDER	ORDER	NNP	I-NP	O
BE	BE	NNP	I-NP	O
USED	USED	NNP	I-NP	O
AS	AS	NNP	I-NP	O
THE	THE	NNP	I-NP	O
D/C	D/C	NNP	I-NP	O
SUMMARY	SUMMARY	NNP	I-NP	O
:	:	:	O	O
YES	YES	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
AVERSANO	AVERSANO	NNP	B-NP	O
,	,	,	O	O
JERRELL	JERRELL	NNP	B-NP	O
MIQUEL	MIQUEL	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
CODE	CODE	NNP	I-NP	O
STATUS	STATUS	NNP	I-NP	O
:	:	:	O	O
Full	Full	JJ	B-NP	O
code	code	NN	I-NP	O
DISPOSITION	DISPOSITION	NN	I-NP	O
:	:	:	O	O
Home	Home	NN	B-NP	O
w	w	NN	I-NP	O
/	/	SYM	B-NP	O
services	service	NNS	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
ASPIRIN	ASPIRIN	NNP	B-NP	O
ENTERIC	ENTERIC	NNP	I-NP	O
COATED	COATED	VBD	B-VP	O
81	81	CD	B-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
DAILY	DAILY	NNP	I-NP	O
LIPITOR	LIPITOR	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
ATORVASTATIN	ATORVASTATIN	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
40	40	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
BEDTIME	BEDTIME	NNP	I-NP	O
CALCIUM	CALCIUM	NN	I-NP	O
+	+	SYM	B-NP	O
D	D	NN	I-NP	O
-LRB-	-LRB-	SYM	O	O
250	250	CD	B-NP	O
MG	MG	NN	I-NP	O
ELEM	ELEM	NN	I-NP	O
.	.	.	O	O

CA	CA	NN	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
CALCIUM	CALCIUM	NN	I-NP	O
CARBON	CARBON	NN	I-NP	O
...	...	:	O	O
-RRB-	-RRB-	SYM	B-NP	B-protein
1	1	CD	I-NP	I-protein
TAB	TAB	NN	I-NP	I-protein
PO	PO	NN	I-NP	I-protein
DAILY	DAILY	NN	I-NP	I-protein
COLACE	COLACE	NN	I-NP	I-protein
-LRB-	-LRB-	NNP	I-NP	I-protein
DOCUSATE	DOCUSATE	NNP	I-NP	I-protein
SODIUM	SODIUM	NNP	I-NP	I-protein
-RRB-	-RRB-	NNP	I-NP	I-protein
100	100	CD	I-NP	I-protein
MG	MG	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
BID	BID	NNP	I-NP	I-protein
FERROUS	FERROUS	NNP	I-NP	I-protein
SULFATE	SULFATE	NNP	I-NP	I-protein
325	325	CD	I-NP	I-protein
MG	MG	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
TID	TID	NNP	I-NP	I-protein
Food/Drug	Food/Drug	NNP	I-NP	I-protein
Interaction	Interaction	NNP	I-NP	I-protein
Instruction	Instruction	NNP	I-NP	I-protein
Avoid	Avoid	NNP	I-NP	I-protein
milk	milk	NN	I-NP	I-protein
and	and	CC	I-NP	O
antacid	antacid	NN	I-NP	O
FEXOFENADINE	FEXOFENADINE	NN	I-NP	O
HCL	HCL	NN	I-NP	O
60	60	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
BID	BID	NNP	I-NP	O
Food/Drug	Food/Drug	NNP	I-NP	O
Interaction	Interaction	NNP	I-NP	O
Instruction	Instruction	NNP	I-NP	O
Avoid	Avoid	NNP	I-NP	O
grapefruit	grapefruit	NN	I-NP	O
unless	unless	IN	B-SBAR	O
MD	MD	NN	B-NP	B-DNA
instructs	instruct	NNS	I-NP	I-DNA
otherwise	otherwise	RB	B-ADVP	O
.	.	.	O	O

LASIX	LASIX	NNP	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
FUROSEMIDE	FUROSEMIDE	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
60	60	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
DAILY	DAILY	NNP	I-NP	O
Starting	Starting	NNP	I-NP	O
Today	Today	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
6/7	6/7	CD	I-NP	O
-RRB-	-RRB-	SYM	O	O
METFORMIN	METFORMIN	NN	B-NP	O
500	500	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
DAILY	DAILY	NNP	I-NP	O
TOPROL	TOPROL	NNP	I-NP	O
XL	XL	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
METOPROLOL	METOPROLOL	NNP	I-NP	O
SUCCINATE	SUCCINATE	NNP	I-NP	O
EXTENDED	EXTENDED	NNP	I-NP	O
RELEASE	RELEASE	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
25	25	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
DAILY	DAILY	NNP	I-NP	O
Food/Drug	Food/Drug	NNP	I-NP	O
Interaction	Interaction	NNP	I-NP	O
Instruction	Instruction	NNP	I-NP	O
Take	Take	NNP	I-NP	O
consistently	consistently	RB	B-ADVP	O
with	with	IN	B-PP	O
meals	meal	NNS	B-NP	O
or	or	CC	B-PP	O
on	on	IN	B-PP	O
empty	empty	JJ	B-NP	O
stomach	stomach	NN	I-NP	O
.	.	.	O	O

SPIRONOLACTONE	SPIRONOLACTONE	NN	B-NP	B-protein
12.5	12.5	CD	I-NP	I-protein
MG	MG	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
DAILY	DAILY	NNP	I-NP	O
Food/Drug	Food/Drug	NNP	I-NP	O
Interaction	Interaction	NNP	I-NP	O
Instruction	Instruction	NNP	I-NP	O
Give	Give	NNP	I-NP	O
with	with	IN	B-PP	O
meals	meal	NNS	B-NP	O
Alert	Alert	NNP	I-NP	O
overridden	overridden	JJ	B-ADJP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
7/12/06	7/12/06	CD	B-NP	O
by	by	IN	B-PP	O
WILDERMAN	WILDERMAN	NNP	B-NP	O
,	,	,	O	O
THANH	THANH	NNP	B-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
POTASSIUM	POTASSIUM	NNP	B-NP	O
CHLORIDE	CHLORIDE	NNP	I-NP	O
&	&	CC	I-NP	O
SPIRONOLACTONE	SPIRONOLACTONE	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
monitor	monitor	NN	B-NP	O
DIOVAN	DIOVAN	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
VALSARTAN	VALSARTAN	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
80	80	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
DAILY	DAILY	NNP	I-NP	O
HOLD	HOLD	NN	I-NP	O
IF	IF	NN	I-NP	O
:	:	:	O	O
SBP	SBP	NN	B-NP	B-protein
<	<	SYM	O	O
90	90	CD	B-NP	O
Alert	Alert	NNP	I-NP	O
overridden	overridden	JJ	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
7/12/06	7/12/06	CD	B-NP	O
by	by	IN	B-PP	O
LESE	LESE	NNP	B-NP	O
,	,	,	O	O
DOYLE	DOYLE	NNP	B-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
POTASSIUM	POTASSIUM	NNP	B-NP	O
CHLORIDE	CHLORIDE	NNP	I-NP	O
&	&	CC	I-NP	O
VALSARTAN	VALSARTAN	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
monitor	monitor	VB	B-VP	O
Number	Number	NNP	B-NP	O
of	of	IN	B-PP	O
Doses	Doses	NNP	B-NP	O
Required	Required	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
approximate	approximate	JJ	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
:	:	:	O	O
4	4	CD	B-NP	O
DIET	DIET	NN	I-NP	O
:	:	:	O	O
House	House	NNP	B-NP	O
/	/	SYM	B-NP	O
Low	Low	JJ	I-NP	O
chol/low	chol/low	NN	I-NP	O
sat	sat	NN	I-NP	O
.	.	.	O	O

fat	fat	JJ	B-NP	O
ACTIVITY	ACTIVITY	NN	I-NP	O
:	:	:	O	O
Walking	Walk	VBG	B-VP	O
as	as	IN	B-SBAR	O
tolerated	tolerate	VBN	B-NP	O
FOLLOW	FOLLOW	NNP	I-NP	O
UP	UP	NNP	I-NP	O
APPOINTMENT	APPOINTMENT	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
S	S	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
:	:	:	O	O
CARDIOLOGY	CARDIOLOGY	NN	B-NP	B-protein
DR	DR	NN	I-NP	I-protein
REVAK	REVAK	NN	I-NP	I-protein
-LRB-	-LRB-	HYPH	B-NP	O
389	389	CD	I-NP	O
-RRB-	-RRB-	HYPH	I-NP	O
710-9257	710-9257	CD	I-NP	O
7/17/06	7/17/06	CD	I-NP	O
@	@	SYM	B-NP	O
3	3	CD	I-NP	O
:	:	SYM	I-NP	O
00	00	CD	I-NP	O
PM	PM	NN	I-NP	O
,	,	,	O	O
ALLERGY	ALLERGY	NN	B-NP	O
:	:	:	O	O
Erythromycins	Erythromycin	NNS	B-NP	O
,	,	,	O	O
LISINOPRIL	LISINOPRIL	NN	B-NP	O
ADMIT	ADMIT	NN	I-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
:	:	:	O	O
SOB	SOB	NN	B-NP	O
PRINCIPAL	PRINCIPAL	JJ	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
;	;	:	O	O
Responsible	Responsible	JJ	B-ADJP	O
After	After	IN	B-PP	O
Study	Study	NNP	B-NP	O
for	for	IN	B-PP	O
Causing	Causing	NNP	B-NP	O
Admission	Admission	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
CHF	CHF	NNP	I-NP	O
OTHER	OTHER	NNP	I-NP	O
DIAGNOSIS	DIAGNOSIS	NNP	I-NP	O
;	;	:	O	O
Conditions	Condition	NNS	B-NP	O
,	,	,	O	O
Infections	Infection	NNS	B-NP	O
,	,	,	O	O
Complications	Complication	NNS	B-NP	O
,	,	,	O	O
affecting	affect	VBG	B-VP	O
Treatment/Stay	Treatment/Stay	NNP	B-NP	O
HTN	HTN	NN	I-NP	O
,	,	,	O	O
DM	DM	NN	B-NP	B-protein
II	II	CD	I-NP	I-protein
,	,	,	O	O
Hypercholesterolemia	Hypercholesterolemia	NN	B-NP	O
,	,	,	O	O
OA	OA	NN	B-NP	O
,	,	,	O	O
PMR	PMR	NN	B-NP	B-protein
,	,	,	O	O
Osteoporosis	Osteoporosis	NN	B-NP	O
,	,	,	O	O
catarcts	catarct	NNS	B-NP	O
.	.	.	O	O

OPERATIONS	OPERATIONS	NNS	B-NP	O
AND	AND	CC	I-NP	O
PROCEDURES	PROCEDURES	NNS	I-NP	O
:	:	:	O	O
MIBI	MIBI	NNP	B-NP	O
OTHER	OTHER	NNP	I-NP	O
TREATMENTS/PROCEDURES	TREATMENTS/PROCEDURES	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
NOT	NOT	NNP	I-NP	O
IN	IN	NNP	I-NP	O
O.R.	O.R.	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Echo	Echo	NNP	I-NP	O
BRIEF	BRIEF	NNP	I-NP	O
RESUME	RESUME	NNP	I-NP	O
OF	OF	IN	B-PP	O
HOSPITAL	HOSPITAL	NNP	B-NP	O
COURSE	COURSE	NNP	I-NP	O
:	:	:	O	O
CC	CC	NN	B-NP	O
:	:	:	O	O
SOB	SOB	NN	B-NP	B-protein
for	for	IN	B-PP	O
1-2	1-2	CD	B-NP	O
weeks	week	NNS	I-NP	O
Dx	Dx	NN	I-NP	O
:	:	:	O	O
CHF	CHF	NN	B-NP	B-protein
****	****	SYM	O	O
HPI	HPI	NN	B-NP	O
:	:	:	O	O
79F	79F	NN	B-NP	O
funciotnal	funciotnal	NN	I-NP	O
,	,	,	O	O
with	with	IN	B-PP	O
HTN	HTN	NN	B-NP	B-protein
,	,	,	O	O
DM	DM	NN	B-NP	B-protein
II	II	CD	I-NP	I-protein
,	,	,	O	O
and	and	CC	O	O
hyperlipidemia	hyperlipidemia	NN	B-NP	O
,	,	,	O	O
who	who	WP	B-NP	O
presents	present	VBZ	B-VP	O
with	with	IN	B-PP	O
1-2	1-2	CD	B-NP	O
weeks	week	NNS	I-NP	O
of	of	IN	B-PP	O
new	new	JJ	B-NP	O
DOE	DOE	NNP	I-NP	O
-	-	HYPH	I-NP	O
reports	report	NNS	I-NP	O
getting	get	VBG	B-VP	O
short	short	JJ	B-ADJP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
after	after	IN	B-PP	O
1	1	CD	B-NP	O
flight	flight	NN	I-NP	O
of	of	IN	B-PP	O
stairs	stair	NNS	B-NP	O
,	,	,	O	O
or	or	CC	O	O
even	even	RB	B-ADVP	O
when	when	WRB	B-ADVP	O
going	go	VBG	B-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
bathroom	bathroom	NN	I-NP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
continue	continue	VBP	B-VP	O
to	to	TO	I-VP	O
preform	preform	VB	I-VP	O
all	all	DT	B-NP	O
ADLs	ADL	NNS	I-NP	B-protein
.	.	.	O	O

She	She	PRP	B-NP	O
also	also	RB	B-ADVP	O
noted	note	VBD	B-VP	O
bilateral	bilateral	JJ	B-NP	O
LEE	LEE	NN	I-NP	O
,	,	,	O	O
PND	PND	NN	B-NP	B-protein
,	,	,	O	O
and	and	CC	O	O
fatigue	fatigue	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
has	have	VBZ	B-VP	O
HTN	HTN	NN	B-NP	B-protein
that	that	WDT	B-NP	O
was	be	VBD	B-VP	O
well-controlled	well-controlled	JJ	B-ADJP	O
,	,	,	O	O
so	so	RB	B-ADVP	O
as	as	IN	B-PP	O
her	her	PRP$	B-NP	B-protein
DM	DM	NN	I-NP	I-protein
II	II	CD	I-NP	I-protein
.	.	.	O	O

Her	Her	PRP$	B-NP	O
last	last	JJ	I-NP	O
Echo	Echo	NNP	I-NP	O
in	in	IN	B-PP	O
2004	2004	CD	B-NP	O
showed	show	VBD	B-VP	O
EF	EF	NN	B-NP	O
of	of	IN	B-PP	O
60	60	CD	B-NP	O
%	%	NN	I-NP	O
with	with	IN	B-PP	O
LVH	LVH	NN	B-NP	B-protein
.	.	.	O	O

ROS	ROS	NN	B-NP	O
is	be	VBZ	B-VP	O
otherwise	otherwise	RB	B-ADJP	O
negative	negative	JJ	I-ADJP	O
for	for	IN	B-PP	O
orthopnea	orthopnea	NN	B-NP	O
,	,	,	O	O
change	change	NN	B-NP	O
in	in	IN	B-PP	O
appetite	appetite	NN	B-NP	O
,	,	,	O	O
or	or	CC	O	O
weight	weight	NN	B-NP	O
,	,	,	O	O
new	new	JJ	B-NP	O
flu	flu	NN	I-NP	O
-	-	HYPH	B-NP	O
like	like	JJ	I-NP	O
symptoms	symptom	NNS	I-NP	O
,	,	,	O	O
history	history	NN	B-NP	O
of	of	IN	B-PP	O
DVT	DVT	NN	B-NP	O
and	and	CC	I-NP	O
pain	pain	NN	I-NP	O
in	in	IN	B-PP	O
calfs	calf	NNS	B-NP	O
.	.	.	O	O

Dx	Dx	NN	B-NP	O
'd	'd	MD	B-VP	O
with	with	IN	B-PP	O
borderline	borderline	JJ	B-NP	O
hyperthyroidism	hyperthyroidism	NN	I-NP	O
few	few	JJ	I-NP	O
months	month	NNS	I-NP	O
ago	ago	RB	B-ADVP	O
,	,	,	O	O
discontinued	discontinue	VBD	B-VP	O
Methimazole	Methimazole	NN	B-NP	O
1	1	CD	I-NP	O
month	month	NN	I-NP	O
ago	ago	RB	B-ADVP	O
.	.	.	O	O

****	****	SYM	B-NP	O
PMH	PMH	NN	I-NP	O
:	:	:	O	O
HTN	HTN	NN	B-NP	B-protein
,	,	,	O	O
DM	DM	NN	B-NP	B-protein
II	II	CD	I-NP	I-protein
,	,	,	O	O
Hyperlipidemia	Hyperlipidemia	NNP	B-NP	O
,	,	,	O	O
OA	OA	NNP	B-NP	O
,	,	,	O	O
S/P	S/P	NNP	B-NP	B-protein
LKR	LKR	NNP	I-NP	I-protein
,	,	,	O	O
B/L	B/L	NN	B-NP	O
hip	hip	NN	I-NP	O
replacement	replacement	NN	I-NP	O
,	,	,	O	O
PMR	PMR	NN	B-NP	B-protein
,	,	,	O	O
Osteroperosis	Osteroperosis	NN	B-NP	O
,	,	,	O	O
pulmonary	pulmonary	JJ	B-NP	O
nodule	nodule	NN	I-NP	O
-LRB-	-LRB-	HYPH	B-NP	O
stable	stable	JJ	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
,	,	,	O	O
hyperthyroidism	hyperthyroidism	NN	B-NP	O
,	,	,	O	O
catarcts	catarct	NNS	B-NP	O
,	,	,	O	O
macular	macular	JJ	B-NP	O
degeneration	degeneration	NN	I-NP	O
.	.	.	O	O

****	****	SYM	O	O
home	home	NN	B-NP	O
meds	med	NNS	I-NP	O
:	:	:	O	O
Triametrene/HCTZ	Triametrene/HCTZ	NN	B-NP	B-protein
,	,	,	O	O
ASA	ASA	NNP	B-NP	O
,	,	,	O	O
Iron	Iron	NNP	B-NP	O
,	,	,	O	O
Metforrmin	Metforrmin	NNP	B-NP	O
,	,	,	O	O
Lipitor	Lipitor	NNP	B-NP	O
,	,	,	O	O
Prilosec	Prilosec	NNP	B-NP	O
,	,	,	O	O
Diovan	Diovan	NNP	B-NP	O
,	,	,	O	O
Calcium	Calcium	NNP	B-NP	O
+	+	SYM	B-NP	O
D	D	NNP	I-NP	O
,	,	,	I-NP	O
Fexofenamine	Fexofenamine	NN	I-NP	O
.	.	.	O	O

****	****	SYM	O	O
Allergies	Allergy	NNPS	B-NP	O
:	:	:	O	O
Erythromycin	Erythromycin	NN	B-NP	O
,	,	,	O	O
ACE-I	ACE-I	NN	B-NP	B-protein
****	****	SYM	B-VP	O
Physical	Physical	JJ	B-NP	O
exam	exam	NN	I-NP	O
on	on	IN	B-PP	O
admission	admission	NN	B-NP	O
:	:	:	O	O
T-97	T-97	NN	B-NP	B-protein
.0	.0	CD	I-NP	I-protein
,	,	,	O	O
HR-60R	HR-60R	NN	B-NP	B-protein
,	,	,	O	O
BP-138	BP-138	NN	B-NP	B-protein
/	/	SYM	B-VP	O
90	90	CD	B-NP	O
,	,	,	O	O
RR-24R	RR-24R	NN	B-NP	B-protein
,	,	,	O	O
O2sat-95	O2sat-95	CD	B-NP	O
%	%	NN	I-NP	O
RA	RA	NN	I-NP	O
NAD	NAD	NN	I-NP	O
,	,	,	O	O
clear	clear	JJ	B-NP	O
o-p	o-p	NN	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
thyromegaly	thyromegaly	RB	I-NP	O
,	,	,	O	O
JVP-16cm	JVP-16cm	NN	B-NP	O
,	,	,	O	O
+	+	SYM	B-NP	O
HJR	HJR	NN	I-NP	B-protein
.	.	.	O	O

Laterally	Laterally	RB	B-NP	O
displaced	displace	VBN	I-NP	O
PMI	PMI	NN	I-NP	O
,	,	,	O	O
RRR	RRR	NN	B-NP	B-protein
,	,	,	O	O
S1	S1	NN	B-NP	B-protein
,	,	,	O	O
S2	S2	NN	B-NP	B-protein
,	,	,	O	O
+	+	CC	O	O
S3	S3	NN	B-NP	B-protein
gallop	gallop	NN	I-NP	I-protein
,	,	,	O	O
on	on	IN	B-PP	O
MRG	MRG	NN	B-NP	B-protein
.	.	.	O	O

Bibasillar	Bibasillar	JJ	B-NP	O
rales	rale	NNS	I-NP	O
in	in	IN	B-PP	O
both	both	DT	B-NP	O
bases	base	NNS	I-NP	O
-LRB-	-LRB-	VBP	B-VP	O
1/3	1/3	CD	B-NP	O
up	up	IN	B-PP	O
-RRB-	-RRB-	NN	B-NP	B-protein
.	.	.	O	O

Abd	Abd	NN	B-NP	B-protein
is	be	VBZ	B-VP	O
soft	soft	JJ	B-ADJP	O
,	,	,	O	O
NTND	NTND	NN	B-NP	B-protein
,	,	,	O	O
no	no	DT	B-NP	O
HSM	HSM	NN	I-NP	B-protein
.	.	.	O	O

Ext	Ext	NN	B-NP	O
-	-	HYPH	B-PP	O
warm	warm	JJ	B-ADJP	O
,	,	,	O	O
2	2	CD	B-NP	O
+	+	SYM	I-NP	O
LEE	LEE	NN	I-NP	O
,	,	,	O	O
peripheral	peripheral	JJ	B-NP	O
LE	LE	NN	I-NP	O
neuropathy	neuropathy	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
loss	loss	NN	I-NP	O
of	of	IN	B-PP	O
proprioception	proprioception	NN	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
DP	DP	NN	I-NP	O
2	2	CD	I-NP	O
+	+	SYM	O	O
/	/	SYM	O	O
2	2	CD	B-NP	O
+	+	SYM	B-NP	O
.	.	.	O	O

****	****	SYM	O	O
Hospital	Hospital	NN	B-NP	O
course	course	NN	I-NP	O
:	:	:	O	O
This	This	DT	B-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
lovely	lovely	JJ	I-NP	O
79	79	CD	I-NP	O
year-old	year-old	JJ	I-NP	O
lady	lady	NN	I-NP	O
with	with	IN	B-PP	O
multiple	multiple	JJ	B-NP	O
risk	risk	NN	I-NP	O
factors	factor	NNS	I-NP	O
for	for	IN	B-PP	O
atheroscosis	atheroscosis	NN	B-NP	O
,	,	,	O	O
including	include	VBG	B-PP	O
long	long	JJ	B-NP	O
standing	standing	NN	I-NP	O
HTN	HTN	NN	I-NP	O
with	with	IN	B-PP	O
evidence	evidence	NN	B-NP	O
of	of	IN	B-PP	O
LVH	LVH	NN	B-NP	B-protein
on	on	IN	B-PP	O
Echo	Echo	NNP	B-NP	O
from	from	IN	B-PP	O
2004	2004	CD	B-NP	O
,	,	,	O	O
DM	DM	NN	B-NP	B-protein
II	II	CD	I-NP	I-protein
complicated	complicate	VBN	B-VP	O
by	by	IN	B-PP	O
neuropathy	neuropathy	NN	B-NP	O
,	,	,	O	O
hyperlipidemia	hyperlipidemia	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
age	age	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
presented	present	VBD	B-VP	O
with	with	IN	B-PP	O
overt	overt	JJ	B-NP	O
symptoms	symptom	NNS	I-NP	O
and	and	CC	O	O
clinical	clinical	JJ	B-NP	O
signs	sign	NNS	I-NP	O
of	of	IN	B-PP	O
congestive	congestive	JJ	B-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
,	,	,	O	O
including	include	VBG	B-PP	O
complaints	complaint	NNS	B-NP	O
of	of	IN	B-PP	O
progressive	progressive	JJ	B-NP	O
shortness	shortness	NN	I-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
,	,	,	O	O
PND	PND	NN	B-NP	B-protein
,	,	,	O	O
fatigue	fatigue	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
peripheral	peripheral	JJ	B-NP	O
edema	edema	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
physical	physical	JJ	I-NP	O
exam	exam	NN	I-NP	O
was	be	VBD	B-VP	O
significant	significant	JJ	B-ADJP	O
for	for	IN	B-PP	O
an	an	DT	B-NP	O
elevated	elevated	JJ	I-NP	O
JVP	JVP	NN	I-NP	O
,	,	,	O	O
lower	low	JJR	B-NP	O
extremity	extremity	NN	I-NP	O
edema	edema	NN	I-NP	O
,	,	,	O	O
pulmonary	pulmonary	JJ	B-NP	O
rales	rale	NNS	I-NP	O
,	,	,	O	O
laterally	laterally	RB	B-ADVP	O
displaced	displace	VBD	B-VP	O
PMI	PMI	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
S3	S3	NN	B-NP	B-protein
gallop	gallop	NN	I-NP	I-protein
,	,	,	O	O
all	all	DT	B-NP	O
consistent	consistent	JJ	B-ADJP	O
with	with	IN	B-PP	O
heart	heart	NN	B-NP	O
failure	failure	NN	I-NP	O
.	.	.	O	O

Even	Even	RB	B-SBAR	O
though	though	IN	I-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
cardiolmegaly	cardiolmegaly	RB	B-ADVP	O
on	on	IN	B-PP	O
CXR	CXR	NN	B-NP	B-protein
from	from	IN	B-PP	O
2004	2004	CD	B-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
LVEF	LVEF	NN	I-NP	B-protein
was	be	VBD	B-VP	O
about	about	RB	B-NP	O
60	60	CD	I-NP	O
%	%	NN	I-NP	O
,	,	,	O	O
suggesting	suggest	VBG	B-VP	O
a	a	DT	B-NP	O
recent	recent	JJ	I-NP	O
development	development	NN	I-NP	O
of	of	IN	B-PP	O
CHF	CHF	NN	B-NP	B-protein
.	.	.	O	O

Her	Her	PRP$	B-NP	O
EKG	EKG	NN	I-NP	B-protein
showed	show	VBD	B-VP	O
NSR	NSR	NN	B-NP	B-protein
with	with	IN	B-PP	O
new	new	JJ	B-NP	O
LBBB	LBBB	NN	I-NP	B-protein
,	,	,	O	O
and	and	CC	O	O
no	no	DT	B-NP	O
QW	QW	NN	I-NP	O
.	.	.	O	O

Due	Due	JJ	B-ADJP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
multiple	multiple	JJ	I-NP	O
atherosclerotic	atherosclerotic	JJ	I-NP	O
risk	risk	NN	I-NP	O
factors	factor	NNS	I-NP	O
,	,	,	O	O
new	new	JJ	B-NP	O
LBBB	LBBB	NNP	I-NP	O
,	,	,	O	O
and	and	CC	O	O
evidence	evidence	NN	B-NP	O
of	of	IN	B-PP	O
neuropathy	neuropathy	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
initial	initial	JJ	I-NP	O
impression	impression	NN	I-NP	O
was	be	VBD	B-VP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
recent	recent	JJ	I-NP	O
ischemic	ischemic	JJ	I-NP	O
event	event	NN	I-NP	O
.	.	.	O	O

Three	Three	CD	B-NP	O
sets	set	NNS	I-NP	O
of	of	IN	B-PP	O
cardiac	cardiac	JJ	B-NP	B-protein
enzymes	enzyme	NNS	I-NP	I-protein
were	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
during	during	IN	B-PP	O
her	her	PRP$	B-NP	O
first	first	JJ	I-NP	O
24	24	CD	I-NP	O
hours	hour	NNS	I-NP	O
stay	stay	VBP	B-VP	O
.	.	.	O	O

She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
stress	stress	NN	I-NP	O
MIBI	MIBI	NN	I-NP	O
showing	show	VBG	B-VP	O
no	no	DT	B-NP	O
scars	scar	NNS	I-NP	O
or	or	CC	I-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
reversible	reversible	JJ	B-NP	O
ischemia	ischemia	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
calculated	calculate	VBN	I-NP	O
EF	EF	NN	I-NP	O
of	of	IN	B-PP	O
23	23	CD	B-NP	O
%	%	NN	I-NP	O
.	.	.	O	O

An	An	DT	B-NP	O
Echo	Echo	NNP	I-NP	O
showed	show	VBD	B-VP	O
dilated	dilated	JJ	B-NP	O
LV	LV	NN	I-NP	O
,	,	,	O	O
with	with	IN	B-PP	O
globaly	globaly	JJ	B-NP	O
reduced	reduce	VBN	I-NP	O
LE	LE	NN	I-NP	O
function	function	NN	I-NP	O
and	and	CC	B-PP	O
near	near	IN	B-PP	O
normal	normal	JJ	B-NP	O
pulmonary	pulmonary	JJ	I-NP	O
pressures	pressure	NNS	I-NP	O
,	,	,	O	O
suggestive	suggestive	JJ	B-ADJP	O
of	of	IN	B-PP	O
dilated	dilated	JJ	B-NP	O
cardiomaypathy	cardiomaypathy	NN	I-NP	O
.	.	.	O	O

Extensive	Extensive	JJ	B-NP	O
interviewing	interviewing	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
patinet	patinet	NN	I-NP	O
was	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
for	for	IN	B-PP	O
other	other	JJ	B-NP	O
possible	possible	JJ	I-NP	O
etiologies	etiology	NNS	I-NP	O
of	of	IN	B-PP	O
HF	HF	NN	B-NP	B-protein
,	,	,	I-NP	O
TSH	TSH	NN	I-NP	O
and	and	CC	I-NP	O
A1C	A1C	NN	I-NP	B-protein
were	be	VBD	B-VP	O
normal	normal	JJ	B-ADJP	O
,	,	,	O	O
and	and	CC	O	O
and	and	CC	O	O
the	the	DT	B-NP	O
cause	cause	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
dilated	dilated	JJ	I-NP	O
CMP	CMP	NN	I-NP	O
remained	remain	VBD	B-VP	O
undifined	undifined	JJ	B-ADJP	O
.	.	.	O	O

she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
diuresed	diurese	VBN	I-VP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
dry	dry	JJ	I-NP	O
weight	weight	NN	I-NP	O
of	of	IN	B-PP	O
57Kg	57Kg	NN	B-NP	O
,	,	,	O	O
responded	respond	VBD	B-VP	O
well	well	RB	B-ADVP	O
to	to	TO	B-PP	O
PO	PO	NNP	B-NP	O
Lasix	Lasix	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
40-60mg	40-60mg	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
,	,	,	O	O
treated	treat	VBN	B-VP	O
also	also	RB	B-ADVP	O
with	with	IN	B-PP	O
Toprol	Toprol	NN	B-NP	O
XL	XL	NN	I-NP	O
25mg	25mg	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
Spironolactone	Spironolactone	NN	B-NP	B-protein
12.5	12.5	CD	I-NP	I-protein
mg	mg	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
symptos	sympto	NNS	I-NP	O
completely	completely	RB	B-ADVP	O
resolved	resolve	VBD	B-VP	O
both	both	CC	B-PP	O
at	at	IN	B-PP	O
rest	rest	NN	B-NP	O
and	and	CC	O	O
with	with	IN	B-PP	O
gentle	gentle	JJ	B-NP	O
ambulation	ambulation	NN	I-NP	O
.	.	.	O	O

One	One	CD	B-NP	O
can	can	MD	B-VP	O
argue	argue	VB	I-VP	O
toward	toward	IN	B-PP	O
evaluating	evaluate	VBG	B-VP	O
her	her	PRP$	B-NP	O
coronaray	coronaray	NN	I-NP	O
arteries	artery	NNS	I-NP	O
either	either	CC	B-PP	O
by	by	IN	B-PP	O
cath	cath	NN	B-NP	O
or	or	CC	I-NP	O
CTA	CTA	NN	I-NP	B-protein
to	to	TO	B-VP	O
exclude	exclude	VB	I-VP	O
balanced	balanced	JJ	B-NP	O
ischemia	ischemia	NN	I-NP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
considering	consider	VBG	B-VP	O
her	her	PRP$	B-NP	O
age	age	NN	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
changed	change	VBD	B-VP	O
in	in	IN	B-PP	O
EKGs	EKG	NNS	B-NP	B-protein
,	,	,	O	O
negative	negative	JJ	B-NP	O
MIBI	MIBI	NNP	I-NP	O
,	,	,	O	O
and	and	CC	O	O
an	an	DT	B-NP	O
Echo	Echo	NNP	I-NP	O
with	with	IN	B-PP	O
globaly	globaly	JJ	B-NP	O
reduced	reduce	VBN	I-NP	O
EF	EF	NN	I-NP	B-protein
,	,	,	O	O
we	we	PRP	B-NP	O
choose	choose	VBP	B-VP	O
to	to	TO	I-VP	O
medicaly	medicaly	RB	I-VP	O
treat	treat	VB	I-VP	O
her	her	PRP	B-NP	O
.	.	.	O	O

she	she	PRP	B-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
evaluated	evaluate	VBN	I-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
future	future	NN	I-NP	O
for	for	IN	B-PP	O
AICD/CRT	AICD/CRT	NN	B-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
a	a	DT	B-NP	O
cath	cath	NN	I-NP	O
can	can	MD	B-VP	O
also	also	RB	I-VP	O
be	be	VB	I-VP	O
considered	consider	VBN	I-VP	O
.	.	.	O	O

She	She	PRP	B-NP	O
will	will	MD	B-VP	O
follow	follow	VB	I-VP	O
up	up	RP	B-PRT	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Rafael	Rafael	NNP	I-NP	O
Abeita	Abeita	NNP	I-NP	O
.	.	.	O	O

ADDITIONAL	ADDITIONAL	JJ	B-NP	O
COMMENTS	COMMENTS	NNS	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Please	Please	VB	B-INTJ	O
go	go	VB	B-VP	O
to	to	TO	B-PP	O
your	your	PRP$	B-NP	O
primary	primary	JJ	I-NP	O
care	care	NN	I-NP	O
within	within	IN	B-PP	O
a	a	DT	B-NP	O
week	week	NN	I-NP	O
to	to	TO	B-VP	O
check	check	VB	I-VP	O
your	your	PRP$	B-NP	O
potassium	potassium	NN	I-NP	O
levles	levle	NNS	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Please	Please	VB	B-VP	O
avoid	avoid	VB	I-VP	O
salty	salty	NN	B-NP	B-protein
food	food	NN	I-NP	I-protein
-LRB-	-LRB-	NN	I-NP	I-protein
and	and	CC	O	O
do	do	VBP	B-VP	O
n't	n't	RB	I-VP	O
add	add	VB	I-VP	O
to	to	TO	B-PP	O
food	food	NN	B-NP	B-protein
-RRB-	-RRB-	NN	I-NP	I-protein
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

weight	weight	NN	B-NP	O
yourself	yourself	PRP	B-NP	O
twice	twice	RB	B-ADVP	O
weekly	weekly	RB	I-ADVP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Attend	Attend	VB	B-VP	O
your	your	PRP$	B-NP	O
appointment	appointment	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
cardiology	cardiology	NN	I-NP	O
clinic	clinic	NN	I-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
CONDITION	CONDITION	NN	I-NP	O
:	:	:	O	O
Stable	Stable	JJ	B-NP	O
TO	TO	NN	I-NP	O
DO/PLAN	DO/PLAN	NN	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Check	Check	NNP	B-NP	O
Chem-7	Chem-7	NNP	I-NP	O
2	2	CD	I-NP	O
.	.	.	O	O

Follow	Follow	JJ	B-NP	O
weight	weight	NN	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

In	In	IN	B-PP	O
six	six	CD	B-NP	O
months	month	NNS	I-NP	O
eval	eval	NN	B-NP	O
for	for	IN	B-PP	O
CRT/AICD	CRT/AICD	NN	B-NP	O
No	No	DT	B-NP	O
dictated	dictated	JJ	I-NP	O
summary	summary	NN	I-NP	O
ENTERED	ENTERED	NNP	I-NP	O
BY	BY	NNP	I-NP	O
:	:	:	O	O
TUMPKIN	TUMPKIN	NNP	B-NP	O
,	,	,	O	O
DOUGLAS	DOUGLAS	NNP	B-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
SY43	SY43	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
10/24/06	10/24/06	CD	I-NP	O
@	@	NN	I-NP	O
11	11	CD	I-NP	O
:	:	:	O	O
47	47	CD	B-NP	O
AM	AM	NN	I-NP	O
******	******	SYM	B-NP	O
END	END	NN	I-NP	O
OF	OF	IN	B-PP	O
DISCHARGE	DISCHARGE	NN	B-NP	O
ORDERS	ORDERS	NNS	I-NP	O
******	******	SYM	B-NP	O

